SOURCE: NuPathe Inc.

NuPathe Inc.

September 01, 2011 16:30 ET

NuPathe to Present at the Stifel Nicolaus Healthcare Conference 2011

CONSHOHOCKEN, PA--(Marketwire - Sep 1, 2011) - NuPathe Inc. (NASDAQ: PATH) today announces that Jane Hollingsworth, chief executive officer, will present a company overview at the Stifel Nicolaus Healthcare Conference 2011 on Thursday, September 8, 2011 at 9:10 a.m. EDT. The conference is being held at the Four Seasons Hotel in Boston, MA.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 30 days following the presentation.

About NuPathe
NuPathe Inc. ( is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 in preclinical development for the long-term treatment of schizophrenia and bipolar disorder.

Contact Information

  • Contact Information:

    John Woolford
    (443) 213-0506

    Keith A. Goldan
    Vice President, Chief Financial Officer
    NuPathe Inc.
    (484) 567-0130